Connect Sign In
ARUP Laboratories is partnering with Augurex Life Sciences Corp. to include the 14-3-3η test in the ARUP test menu to enhance the early detection of rheumatoid arthritis.
ARUP has been awarded a CDC contract for avian influenza A (H5N1) test development, which recognizes our expertise and experience with assay development and our desire to serve public health needs.
The new Sherrie Perkins Research and Innovation Collaboration Grant, designed to foster collaboration in healthcare, will fund cutting-edge research in lab medicine that could impact patient care.
ARUP’s declaration amplifies the lawsuit’s claims that the FDA does not have legal authority over laboratory testing services and that regulating these services is unreasonable.
ARUP maintains that the FDA’s rule will limit access to testing, stifle innovation, and increase healthcare costs.
A new partnership between ARUP and connectivity provider ELLKAY aims to give health systems the testing support, guidance, and technology needed to establish or expand lab outreach operations.
Nearly 85% of respondents to an ARUP survey believe the FDA’s proposed rule to regulate lab-developed tests will negatively impact their labs. Only 3% believe they have the financial resources to comply.
ARUP and the University of Utah Department of Pathology have announced that ARUP’s executive vice president, Julio Delgado, MD, MS, will be the inaugural holder of a new presidential endowed chair.
ARUP and Medicover have partnered to provide a new companion diagnostic test to European Union patients. The test helps identify individuals eligible for a new gene therapy for severe hemophilia A.
Utah Business magazine honored ARUP Laboratories with its Best Companies to Work For award for the sixth consecutive year based on anonymous employee survey results.
